New hope for nerve disease: immune therapy trial targets long-term control

NCT ID NCT06752356

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher or lower dose for 24 weeks to see which better improves disability scores. The goal is to control the disease long-term, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Advanced Neurology Epilepsy and Sleep Center/ANESC Research

    RECRUITING

    El Paso, Texas, 79912, United States

    Contact

  • Dartmouth-Hitchcock Medical Center

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact

  • USF Health - Morsani Center for Advanced Healthcare

    RECRUITING

    Tampa, Florida, 33613, United States

    Contact